Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 75 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Context Small single-center studies have shown that cerebrospinal fluid (CSF) biomarkers may be useful to identify incipient Alzheimer disease (AD) in patients with mild cognitive impairment (MCI), but large-scale multicenter studies have not been conducted. Objective To determine the diagnostic accuracy of CSF beta-amyloid(1-42) (Abeta42), total tau protein (T-tau), and tau phosphorylated at position threonine 181 (P-tau) for predicting incipient AD in patients with MCI. Design, setting, and participants The study had 2 parts: a cross-sectional study involving patients with AD and controls to identify cut points, followed by a prospective cohort study involving patients with MCI, conducted 1990-2007. A total of 750 individuals with MCI, 529 with AD, and 304 controls were recruited by 12 centers in Europe and the United States. Individuals with MCI were followed up for at least 2 years or until symptoms had progressed to clinical dementia. Main outcome measures Sensitivity, specificity, positive and negative likelihood ratios (LRs) of CSF Abeta42, T-tau, and P-tau for identifying incipient AD. Results During follow-up, 271 participants with MCI were diagnosed with AD and 59 with other dementias. The Abeta42 assay in particular had considerable intersite variability. Patients who developed AD had lower median Abeta42 (356; range, 96-1075 ng/L) and higher P-tau (81; range, 15-183 ng/L) and T-tau (582; range, 83-2174 ng/L) levels than MCI patients who did not develop AD during follow-up (579; range, 121-1420 ng/L for Abeta42; 53; range, 15-163 ng/L for P-tau; and 294; range, 31-2483 ng/L for T-tau, P Conclusions This multicenter study found that CSF Abeta42, T-tau, and P-tau identify incipient AD with good accuracy, but less accurately than reported from single-center studies. Intersite assay variability highlights a need for standardization of analytical techniques and clinical procedures.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 750 participants. The authors say these markers identified incipient Alzheimer's "with good accuracy, but less accurately than reported from single-center studies", and that the amyloid-beta test varied considerably between sites, so they called for standardised lab methods. The study measured prediction only; the values for the two groups overlapped widely, so a single result cannot say for certain what will happen to one person.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., et al. (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. https://doi.org/10.1001/jama.2009.1064

Vancouver

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009. doi:10.1001/jama.2009.1064. PMID: 19622817.

BibTeX

@article{mattsson2009-19622817,
  author  = {Mattsson, N. and Zetterberg, H. and Hansson, O. and Andreasen, N. and Parnetti, L. and Jonsson, M. and Herukka, S. K. and van der Flier, W. M. and others},
  title   = {{CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment}},
  journal = {JAMA},
  year    = {2009},
  doi     = {10.1001/jama.2009.1064},
  pmid    = {19622817},
  url     = {https://doi.org/10.1001/jama.2009.1064}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In 750 people with mild cognitive impairment followed for at least two years across 12 centres in Europe and the US, the 271 who went on to be diagnosed with Alzheimer's had, at the start, lower spinal-fluid amyloid-beta 42 and higher total tau and phosphorylated tau than those who did not. The authors say these markers identified incipient Alzheimer's "with good accuracy, but less accurately than reported from single-center studies", and that the amyloid-beta test varied considerably between sites, so they called for standardised lab methods. The study measured prediction only; the values for the two groups overlapped widely, so a single result cannot say for certain what will happen to one person.

Study details

How this study scored 75/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 5 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 75 of 100.75 of 100 points earned25 not earned

Published in a top-tier journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (JAMA)
Journal's citation record 4 / 4 JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2009 — within 20 year(s) of the newest study here
Sample size 2 / 4 750 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 1,171 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 61.6 citations a year over 19 year(s) since 2009
Impact for its field and year 6 / 6 Cited 65.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 5 / 6 Cited by 108 other studies in this library
Still being cited 3 / 4 Cited 69 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Niklas Mattsson: h-index 109 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Gothenburg: institution h-index 972 (OpenAlex)
Multicenter collaboration 2 / 3 PubMed indexes it as a multicentre study
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 19622817)
Free to read 0 / 2 Behind a paywall — scores zero
Total 75 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.

Later studies that cite this one

108 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →